We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A new strategy to ERADicate HER2-positive breast tumors?
- Authors
Arora, Sanjeevani; Golemis, Erica A.
- Abstract
HER2-positive breast cancers that have become resistant to HER2-targeting agents, such as trastuzumab (also known as Herceptin), have limited treatment options. In this issue of Science Signaling, Singh et al. have identified a characteristic increase in the endoplasmic reticulum (ER)-associated degradation (ERAD) system in HER2-positive tumors as a mechanism of relieving proteotoxic stress. Synthetic lethality arising from targeted disruption of ERAD signaling in conjunction with other HER2-dependent signaling may improve therapeutic management of this difficult class of breast tumors.
- Subjects
HER2 gene; BREAST cancer treatment; TRASTUZUMAB; ENDOPLASMIC reticulum; BREAST tumor treatment; PROTEIN kinases; DEGLYCOSYLATION; UBIQUITINATION; PHYSIOLOGY
- Publication
Science Signaling, 2015, Vol 8, Issue 378, p1
- ISSN
1945-0877
- Publication type
Article
- DOI
10.1126/scisignal.aac4746